LILACS – Literatura Latinoamericana y del Caribe de Ciencias de la Salud

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors

Buzatto, IPC; Ribeiro-Silva, A; Andrade, JM; Carrara, HHA; Silveira, WA; Tiezzi, DG.

Braz. j. med. biol. res; 50 (2), 2017

The purpose of this study was to retrospectively review the pathologic complete response (pCR) rate from patients (n=86) with stage II and III HER2-positive breast cancer treated with neoadjuvant chemotherapy at our institution from 2008 to 2013 and to determine possible predictive and prognostic factors...

Antineoplásicos/administración & dosificación, Biomarcadores de Tumor/sangre, Neoplasias de la Mama/tratamiento farmacológico, Neoplasias de la Mama/cirugía, Quimioterapia Adyuvante/métodos, Inmunohistoquímica, Estimación de Kaplan-Meier, Antígeno Ki-67/sangre, Mastectomía, Estadificación de Neoplasias, Pronóstico, Receptor ErbB-2/sangre, Receptores de Estrógenos/sangre, Receptores de Progesterona/sangre, Estudios Retrospectivos, Trastuzumab/administración & dosificación

Fulltext

Her2 expression as a prognostic factor in metastatic gastric cancer

ABSTRACT Background - Human epidermal growth factor receptor 2 (EGFR2/HER2/ErbB2) is a transmembrane receptor that stimulates cell proliferation when activated. The correlation of HER2 expression with prognosis has been studied in many cancer types. However, its relationship with survival of patients ...